Source comparison
CJC-1295 Animal vs Human Research: Side-by-Side Comparison
Rodent (Teichman 2006) 30–300 mcg/kg 40–60% above baseline, linear with dose 200–300% above baseline 6–8 days confirmed Not observed in 90-day protocols Clean proof-of-concept data. Overestimates human magnitude of effect Human Phase I/II (Teichman 2008) 30–90
This comparison does not assign a generated winner or score.
- Rodent (Teichman 2006)
- 30–300 mcg/kg
- 40–60% above baseline, linear with dose
- 200–300% above baseline
- 6–8 days confirmed
- Not observed in 90-day protocols
- Clean proof-of-concept data. Overestimates human magnitude of effect
- Human Phase I/II (Teichman 2008)
- 30–90 mcg/kg
- 50–100% above baseline, plateaus above 60 mcg/kg
- 50–80% above baseline
- Anti-CJC-1295 antibodies in 8–12% by week 12
- Mechanism translates, but dose-response curve and immune risk differ significantly
- Rodent toxicology (13-week)
- Up to 1,000 mcg/kg weekly
- Proportional IGF-1 response at all doses
- Sustained without desensitization
- Not applicable (acute dosing)
- None detected
- Safety margin appears wide in controlled short-term studies
- Human extended dosing (observational)
- 60 mcg/kg biweekly × 24 weeks
- IGF-1 response attenuates after week 16 in subset of subjects
- Variability increases with prolonged exposure
- Unchanged
- Neutralizing antibodies in 2–3% of long-term users
- Extended exposure increases immunogenicity risk not captured in rodent models